CADTH and Canadian Blood Services Interim Plasma Protein Product Review Process

1. Canadian Plasma Protein Product Expert Committee

CADTH and Canadian Blood Services announced the establishment of the Interim Plasma Protein Product (PPP) review process in November 2019. As part of the interim process, CADTH and Canadian Blood Services have established the Canadian Plasma Protein Product Expert Committee (CPEC) to provide reimbursement recommendations for eligible products (i.e., those representing new categories to the Canadian Blood Services formulary).

The CPEC has been formed as a subcommittee of the Canadian Drug Expert Committee (CDEC), with the following additional members who have expertise in the diagnosis and management of blood disorders and the use of plasma protein products and related alternatives.

**Dr. Irene Sadek MBBCh, MSc, FRCPC**

Dr. Sadek is the Department Head of Pathology at Dalhousie University and Nova Scotia Health Authority (NSHA) (Central Zone). She has been working as a hematopathologist at the Queen Elizabeth II Health Sciences Centre Health Sciences Centre since 1998 and became Head of the Division of Hematopathology in 2003. She was also the Director of the Blood Transfusion Service at Capital District Health Authority and NSHA (Central Zone) and Chair of the Advisory Committee for the Nova Scotia Blood Coordinating Program. Dr. Sadek was the Program Director for Hematological Pathology Residency Training and started a Transfusion Medicine Fellowship Training Program at Dalhousie University in 2004 that she chaired for 10 years. She is currently the chair of the Royal College Specialty Training Committee in Hematological Pathology. Until recently, she was a member of the Canadian National Advisory Committee on Blood and Blood Products. She has a great interest in appropriate utilization and was the Canadian Society of Transfusion Medicine lead for the Choosing Wisely Canada initiative. Dr. Sadek continues to serve on many provincial and national committees and has been involved with the new initiative of Choosing Wisely Nova Scotia.

**Dr. Andrew Shih MD, MSc**

Dr. Shih works as the Transfusion Medicine Regional Medical Leader at Vancouver Coastal Health Authority, a University of British Columbia Clinical Assistant Professor in the Department of Pathology and Laboratory Medicine, and a primary investigator at the
University of British Columbia Centre for Blood Research. He trained as a clinical hematologist/transfusion medicine physician and completed a thesis-based masters in the Health Research Methodology program through the Ministry of Health Clinical Investigator Program at McMaster University. His research interests include promotion and education regarding the safety and appropriate utilization of blood products and cell therapeutics; as well as advancing blood transfusion as a personalized medical therapeutic intervention.

2. Next Steps for the Interim PPP Process

CADTH and Canadian Blood Services look forward to working with CPEC and all stakeholders to ensure that plasma protein products are reviewed in a timely, inclusive, and evidence-based manner.

As previously communicated, the interim PPP process will be in place while provincial and territorial governments (with the exception of Quebec) complete a review of PPPs and drug formulary processes in collaboration with Canadian Blood Services, CADTH, as well as other key stakeholders.